Comparative study with monospecific and monoclonal antibodies gainst a 65 K human cytomegalovirus protein

1988 ◽  
Vol 101 (1-2) ◽  
pp. 79-86 ◽  
Author(s):  
K. Shimokawa ◽  
Xu Bin ◽  
T. Furukawa
Keyword(s):  
Monoclonal Antibodies ◽  
Comparative Study ◽  
Human Cytomegalovirus

scholarly journals Neutralizing Mechanisms of Two Human Monoclonal Antibodies Against Human Cytomegalovirus Glycoprotein 130/55

1992 ◽  
Vol 73 (10) ◽  
pp. 2705-2707 ◽  
Author(s):  
Y. Ohizumi ◽  
H. Suzuki ◽  
Y.-I. Matsumoto ◽  
Y. Masuho ◽  
Y. Numazaki
Keyword(s):  
Monoclonal Antibodies ◽  
Human Cytomegalovirus ◽  
Human Monoclonal Antibodies

Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: A comparative study with CHO produced materials

Biologicals ◽  
2011 ◽  
Vol 39 (4) ◽  
pp. 205-210 ◽  
Author(s):  
Liming Liu ◽  
Andy Stadheim ◽  
Lora Hamuro ◽  
Tamara Pittman ◽  
Weirong Wang ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Pichia Pastoris ◽  
Comparative Study

scholarly journals Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection

2020 ◽  
Author(s):  
Matthew L. Goodwin ◽  
Helen S. Webster ◽  
Hsuan-Yuan Wang ◽  
Jennifer A. Jenks ◽  
Cody S. Nelson ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Human Cytomegalovirus ◽  
Effector Cell ◽  
Natural Infection ◽  
Congenital Infection ◽  
Neutralizing Antibody ◽  
Antibody Responses ◽  
Domain Specificity ◽  
Cell Functions ◽  
The Impact

AbstractHuman cytomegalovirus (HCMV) is the most common congenital infection, and the leading nongenetic cause of sensorineural hearing loss (SNHL) in newborns globally. A gB subunit vaccine administered with adjuvent MF59 (gB/MF59) is the most efficacious tested to-date, achieving 50% efficacy in preventing infection of HCMV-seronegative mothers. We recently discovered that gB/MF59 vaccination elicited primarily non-neutralizing antibody responses, that HCMV strains acquired by vaccinees more often included strains with gB genotypes that are distinct from the vaccine antigen, and that protection against HCMV acquisition correlated with ability of vaccine-elicited antibodies to bind to membrane associated gB. Thus, we hypothesized that gB-specific non-neutralizing antibody binding breadth and function are dependent on their epitope and genotype specificity as well as their ability to interact with membrane-associated gB. Twenty-four gB-specific monoclonal antibodies (mAbs) isolated from naturally HCMV-infected individuals were mapped for gB domain specificity by binding antibody multiplex assay (BAMA) and for genotype preference binding to membrane-associated gB presented on transfected cells. We defined their non-neutralizing functions including antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC). The isolated gB-specific non-neutralizing mAbs were primarily specific for Domain II and linear antigenic domain 2 site 2 (AD2). We observed variability in mAb gB genotype binding preference, with increased binding to gB genotypes 2 and 4. Functional studies identified two gB-specific mAbs that facilitate ADCP and have binding specificities of AD2 and Domain II. This investigation provides novel understanding on the impact of gB domain specificity and antigenic variability on gB-specific non-neutralizing antibody responses.ImportanceHCMV is the most common congenital infection worldwide, but development of a successful vaccine remains elusive. gB-specific non-neutralizing mAbs, represent a distinct anti-HCMV Ab subset implicated in the protection against primary infection during numerous phase-II gB/MF59 vaccine trials. By studying non-neutralizing gB-specific mAbs from naturally infected individuals, this study provides novel characterization of binding site specificity, genotypic preference, and effector cell functions mediated by mAbs elicited in natural infection. We found that a panel of twenty-four gB-specific non-neutralizing mAbs bind across multiple regions of the gB protein, traditionally through to be targeted by neutralizing mAbs only, and bind differently to gB depending if the protein is soluble versus embedded in a membrane. This investigation provides novel insight into the gB-specific binding characteristics and effector cell functions mediated by non-neutralizing gB-specific mAbs elicited through natural infection, providing new endpoints for future vaccine development.

Production of Monoclonal Antibodies Against Phosphoprotein 65 from Human Cytomegalovirus

Hybridoma ◽  
2007 ◽  
Vol 26 (3) ◽  
pp. 173-177 ◽  
Author(s):  
Li-Jun Xu ◽  
Hang-Ping Yao ◽  
Jun Fan ◽  
Dan Li ◽  
Nan-Ping Wu
Keyword(s):  
Monoclonal Antibodies ◽  
Human Cytomegalovirus

Development of Human Monoclonal Antibodies Against Human Cytomegalovirus

Hybridoma ◽  
1992 ◽  
Vol 11 (5) ◽  
pp. 569-579 ◽  
Author(s):  
YOSHIAKI KANOH ◽  
MIKIHIRO YUNOKI ◽  
TOMOKUNI TANIGUCHI ◽  
YUKIO SUZUKI ◽  
SHOJI IDENO ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Human Cytomegalovirus ◽  
Human Monoclonal Antibodies

Two different anti-erythroid monoclonal antibodies in immunodiagnosis of human leukemias: A comparative study

1989 ◽  
Vol 44 (4) ◽  
pp. 589-592 ◽  
Author(s):  
N. N. Tupitsyn ◽  
E. B. Mechetner ◽  
A. Ju. Baryschnikov ◽  
T. S. Drozdova ◽  
M. A. Frenkel ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Comparative Study

scholarly journals Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas

Vaccines ◽  
2019 ◽  
Vol 7 (4) ◽  
pp. 135 ◽  
Author(s):  
Takako Tabata ◽  
Matthew Petitt ◽  
June Fang-Hoover ◽  
Daniel C. Freed ◽  
Fengsheng Li ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Human Cytomegalovirus ◽  
Virus Transmission ◽  
Passive Immunization ◽  
First Trimester ◽  
Clinical Strain ◽  
Stromal Fibroblasts ◽  
Virion Assembly ◽  
Effective Strategies ◽  
Hyperimmune Globulin

Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects worldwide, yet the most effective strategies for preventing virus transmission during pregnancy are unknown. We measured the efficacy of human monoclonal antibodies (mAbs) to HCMV attachment/entry factors glycoprotein B (gB) and the pentameric complex, gH/gL-pUL128–131, in preventing infection and spread of a clinical strain in primary placental cells and explants of developing anchoring villi. A total of 109 explants from five first-trimester placentas were cultured, and infection was analyzed in over 400 cell columns containing ~120,000 cytotrophoblasts (CTBs). mAbs to gB and gH/gL, 3-25 and 3-16, respectively, neutralized infection in stromal fibroblasts and trophoblast progenitor cells. mAbs to pUL128-131 of the pentameric complex, 1-103 and 2-18, neutralized infection of amniotic epithelial cells better than mAbs 3-25 and 3-16 and hyperimmune globulin. Select mAbs neutralized infection of cell column CTBs, with mAb 2-18 most effective, followed by mAb 3-25. Treatment of anchoring villi with mAbs postinfection reduced spread in CTBs and impaired formation of virion assembly compartments, with mAb 2-18 achieving better suppression at lower concentrations. These results predict that antibodies generated by HCMV vaccines or used for passive immunization have the potential to reduce transplacental transmission and congenital disease.

Sign in / Sign up

Export Citation Format

Share Document